Company Overview

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

  • Name

    Moderna, Inc.

  • CEO

    Mr. Stephane Bancel

  • Website

    www.modernatx.com

  • Sector

    Biotechnology

  • Year Founded

    2010

Profile

  • Market Cap

    $26.85B

  • EV

    $17.31B

  • Shares Out

    384.4M

  • Revenue

    $5,050M

  • Employees

    5,600

Margins

  • Gross

    -62.99%

  • EBITDA

    -81.33%

  • Operating

    -91.78%

  • Pre-Tax

    -85.78%

  • Net

    -116.18%

  • FCF

    -78.79%

Returns (5Yr Avg)

  • ROA

    8.99%

  • ROTA

    21.64%

  • ROE

    21.65%

  • ROCE

    24.34%

  • ROIC

    0.21%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    $99.84

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $8,488M

  • Net Debt

    -$9,545M

  • Debt/Equity

    0.11

  • EBIT/Interest

    -165.54

Growth (CAGR)

  • Rev 3Yr

    -10.39%

  • Rev 5Yr

    116.45%

  • Rev 10Yr

  • Dil EPS 3Yr

    21.94%

  • Dil EPS 5Yr

    45.6%

  • Dil EPS 10Yr

  • Rev Fwd 2Yr

    -29.64%

  • EBITDA Fwd 2Yr

    -67.53%

  • EPS Fwd 2Yr

    -72.29%

  • EPS LT Growth Est

    -24.58%

Dividends

  • Yield

  • Payout

  • DPS

  • DPS Growth 3Yr

  • DPS Growth 5Yr

  • DPS Growth 10Yr

  • DPS Growth Fwd 2Yr

NasdaqGS:MRNA